Fortune China unveiled the latest “Fortune China 500” list on its website on July 10, 2019. Huadong Medicine Co., Ltd. (hereinafter “Huadong Medicine”) ranks 287th on the list. This is the eighth successive year that Huadong Medicine was inscribed onto the list.

This year’s “Fortune China 500” list, released on the website of Fortune China, was jointly compiled by the Fortune magazine (Chinese version) and the CICC Wealth Management Department. The ranking list evaluated the global performance and achievements of China’s largest listed companies in 2018.

In recent years, the implementation of such policies as the two-vote system, generic drug consistency evaluation and centralized procurement has increased the operational pressure faced by pharmaceutical enterprises, and brought about tremendous changes in market competition landscape. In this context, Huadong Medicine has constantly promoted reform and innovation, achieving a steady development and fruitful achievements. In 2018, it acquired all stakes of British pharmaceutical company Sinclair, which marked an important step in implementing its strategy to “go global” and would enable Huadong Medicine to directly obtain a world-class medicine and cosmetics production lines, an international sales network and intellectual property rights. This is conducive to fostering new business growth points. Moreover, the acquisition was ranked among the top 10 IPOs, top 10 M&A cases and top 10 organizations of Zhejiang’s capital market in 2018 by Zhejiang Investment M&A Association, and inscribed onto the List of Fenghuang Companies 2018 as one of the 10 largest M&A cases.

Meanwhile, guided by the strategy of technological transformation that “attaches equal importance to innovation and first generics,” Huadong Medicine increases investment in R&D and has formed a new drug R&D model “integrating independent R&D, cooperative and commissioned R&D and license-in.” It has continuously introduced innovative products and projects, realizing positive results. In the future, the company will continue promoting innovative strategic transformation and development, so as to strengthen and enhance its competitiveness.

As the world’s second largest medical and pharmaceutical market, China is gradually transforming from a big country in medicine to a strong power in pharmaceutical innovation. With a keen insight into the direction of transformation and upgrading of the industry, Huadong Medicine has spared no efforts to join the “race” of R&D innovation among pharmaceutical enterprises and actively participate in international M&A, with an aim to become a leading enterprise in the field of special drugs in China and an internationalized pharmaceutical giant.